Rheden, Netherlands

Franciscus B G Benneker

This inventor holds 9 USPTO granted patents. Top assignees: Synthon B.v., Synthon IP Inc.. Active years: 2002-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Franciscus B G Benneker. Retrieved from https://idiyas.com/inventor/franciscus-b-g-benneker

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 3.4

ph-index = 6

Forward Citations = 95(Granted Patents)


Company Filing History:


Years Active: 2002-2008

Loading Chart...
9 patents (USPTO):Explore Patents

Title: The Innovations of Franciscus B G Benneker

Introduction

Franciscus B G Benneker is a notable inventor based in Rheden, Netherlands. He has made significant contributions to the field of pharmaceuticals, holding a total of nine patents. His work focuses on innovative formulations that enhance the effectiveness of medications.

Latest Patents

One of his latest patents is for an Amlodipine free base, which can be formulated into a convenient oral dosage form, particularly a tablet, without excessive stickiness or tablet punch residue. This formulation can utilize crystalline Form I or a novel Form II. Another significant patent is for an amide derivative of amlodipine, which is useful as a pharmaceutical, either alone or in combination with amlodipine, in treating angina and hypertension.

Career Highlights

Throughout his career, Benneker has worked with prominent companies such as Synthon B.V. and Synthon IP Inc. His innovative approaches have contributed to advancements in pharmaceutical formulations, making medications more accessible and effective for patients.

Collaborations

He has collaborated with notable coworkers, including Theodorus H A Peters and Jacobus Maria Lemmens, who have also contributed to the field of pharmaceutical innovations.

Conclusion

Franciscus B G Benneker's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents reflect a commitment to improving medication formulations, ultimately benefiting patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…